After publication of the original article [1], the authors have notified us of 5 errors which are highlighted below. The authors apologize for any inconvenience.
1.
“ca-199 (tissue) (U/mL)” in Table 1 was incorrectly presented and should be replaced with “ca-199 (serum) (U/mL)”.
2.
“miR-143-3p” in Table 2 was a mistake in spelling and should be replaced with “miR-149-3p”.
3.
We have corrected the 48h representation in Fig. 5.
Fig. 5
MiR-149-3p suppressed GC cell proliferation and migration. a, b The CCK-8 assays were performed in SGC-7901 and MGC-803 cells transfected with mimics or miR-NC (Two-way ANOVA). c, d The wound healing assays were performed in SGC-7901 and MGC-803 cells transfected with mimics or miR-NC. Mimics: 149-3p mimics; miR-NC: miR-149-3p negative control. *P < 0.05; **P < 0.01
×
4.
We have corrected the cell migration vector representation and the cell invasion LV-Z+miR-149-3p representation in Fig. 8.
Fig. 8
MiR-149-3p partially abolished GC cell migration and invasion induced by ZEB1-AS1. a, b ZEB1-AS1-induced cell migration and invasion were partly abrogated by miR-149-3p (Two-way ANOVA). *P < 0.05; **P < 0.01
×
5.
The primer sequences with red color were out-of-order for the wrong type setting of Microsoft Word. Accordingly, we corrected it.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
